U.S. Markets open in 3 hrs 43 mins
  • S&P Futures

    3,756.50
    -0.25 (-0.01%)
     
  • Dow Futures

    30,026.00
    +44.00 (+0.15%)
     
  • Nasdaq Futures

    11,513.25
    -28.50 (-0.25%)
     
  • Russell 2000 Futures

    1,761.80
    +3.70 (+0.21%)
     
  • Crude Oil

    88.92
    +0.47 (+0.53%)
     
  • Gold

    1,720.00
    -0.80 (-0.05%)
     
  • Silver

    20.81
    +0.15 (+0.70%)
     
  • EUR/USD

    0.9803
    +0.0008 (+0.0784%)
     
  • 10-Yr Bond

    3.8260
    0.0000 (0.00%)
     
  • Vix

    30.31
    +1.76 (+6.16%)
     
  • GBP/USD

    1.1193
    +0.0024 (+0.2171%)
     
  • USD/JPY

    144.8450
    -0.2230 (-0.1537%)
     
  • BTC-USD

    19,983.42
    -192.27 (-0.95%)
     
  • CMC Crypto 200

    454.83
    -8.29 (-1.79%)
     
  • FTSE 100

    7,009.78
    +12.51 (+0.18%)
     
  • Nikkei 225

    27,116.11
    -195.19 (-0.71%)
     

Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference

·1 min read

CAMBRIDGE, Mass., September 02, 2022--(BUSINESS WIRE)--Oak Hill Bio ("Oak Hill"), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that members of its senior leadership team will participate in one-on-one meetings with investors at the upcoming Citi 17th Annual BioPharma Conference taking place on September 7-8, 2022, in Boston, MA.

For additional information or to schedule a one-on-one meeting with members of the Oak Hill management team, please contact your Citi representative.

About Oak Hill Bio

Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The company, which has operations in the United States and United Kingdom, was launched to develop a pipeline of six promising clinical-stage and preclinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited ("Takeda"). For more information on Oak Hill Bio, visit the company’s website at www.oakhillbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220902005258/en/

Contacts

Investors
Josh Distler
Oak Hill Bio
josh.distler@oakhillbio.com

Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
212-362-1200

Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936